BR112015031509A2 - Polipeptídeo, molécula de ácido nucleico, vetor, e, composição - Google Patents

Polipeptídeo, molécula de ácido nucleico, vetor, e, composição

Info

Publication number
BR112015031509A2
BR112015031509A2 BR112015031509A BR112015031509A BR112015031509A2 BR 112015031509 A2 BR112015031509 A2 BR 112015031509A2 BR 112015031509 A BR112015031509 A BR 112015031509A BR 112015031509 A BR112015031509 A BR 112015031509A BR 112015031509 A2 BR112015031509 A2 BR 112015031509A2
Authority
BR
Brazil
Prior art keywords
polypeptide
vector
composition
nucleic acid
acid molecule
Prior art date
Application number
BR112015031509A
Other languages
English (en)
Other versions
BR112015031509B1 (pt
Inventor
Petrus Maria Langedijk Johannes
Krarup Anders
Original Assignee
Crucell Holland Bv
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv, Janssen Vaccines & Prevention Bv filed Critical Crucell Holland Bv
Publication of BR112015031509A2 publication Critical patent/BR112015031509A2/pt
Publication of BR112015031509B1 publication Critical patent/BR112015031509B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135—Respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2999/00—Further aspects of viruses or vectors not covered by groups C12N2710/00 - C12N2796/00 or C12N2800/00
    • C12N2999/002—Adverse teaching

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cosmetics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)

Abstract

POLIPEPTÍDEO, MOLÉCULA DE ÁCIDO NUCLEICO, VETOR, E, COMPOSIÇÃO. A presente invenção proporciona polipeptídeos F do vírus sincicial respiratório (RSV) pré-fusão estáveis, composições imunogênicas compreendendo os referidos polipeptídeos e seus usos para a prevenção e/ou tratamento de infecção por RSV.
BR112015031509-7A 2013-06-17 2014-06-17 Polipeptídeo de fusão (f) do vírus sincicial respiratório (rsv) pré- fusão recombinante e composição que o compreende BR112015031509B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13172256.3 2013-06-17
EP13172256 2013-06-17
PCT/EP2014/062655 WO2014202570A1 (en) 2013-06-17 2014-06-17 Stabilized soluble pre-fusion rsv f polypeptides

Publications (2)

Publication Number Publication Date
BR112015031509A2 true BR112015031509A2 (pt) 2017-08-29
BR112015031509B1 BR112015031509B1 (pt) 2023-05-09

Family

ID=48625910

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015031509-7A BR112015031509B1 (pt) 2013-06-17 2014-06-17 Polipeptídeo de fusão (f) do vírus sincicial respiratório (rsv) pré- fusão recombinante e composição que o compreende

Country Status (20)

Country Link
US (1) US10294279B2 (pt)
EP (1) EP3010931B1 (pt)
JP (1) JP6679475B2 (pt)
KR (1) KR102313153B1 (pt)
CN (1) CN105408348B (pt)
AP (1) AP2015008893A0 (pt)
AU (1) AU2014283334B2 (pt)
BR (1) BR112015031509B1 (pt)
CA (1) CA2914792C (pt)
CL (1) CL2015003655A1 (pt)
EA (1) EA034653B1 (pt)
HK (1) HK1223949A1 (pt)
IL (1) IL243053B (pt)
MX (1) MX362792B (pt)
MY (1) MY171210A (pt)
PE (1) PE20160045A1 (pt)
PH (1) PH12015502735A1 (pt)
SG (1) SG11201510216RA (pt)
WO (1) WO2014202570A1 (pt)
ZA (1) ZA201509140B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2015008815A0 (en) 2013-04-25 2015-10-31 Crucell Holland Bv Stabilized soluble prefusion rsv f polypeptides
PE20160045A1 (es) 2013-06-17 2016-02-18 Crucell Holland Bv Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados
CN116059336A (zh) 2015-07-07 2023-05-05 扬森疫苗与预防公司 针对rsv的疫苗
WO2017005848A1 (en) 2015-07-07 2017-01-12 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f polypeptides
RU2723039C2 (ru) 2015-12-23 2020-06-08 Пфайзер Инк. Мутанты белка f rsv
KR102401247B1 (ko) 2016-04-05 2022-05-25 얀센 백신스 앤드 프리벤션 비.브이. Rsv에 대한 백신
SI3439672T1 (sl) 2016-04-05 2021-02-26 Janssen Vaccines & Prevention B.V. Stabiliziran topen pre-fuzijski F protein RSV za uporabo v profilaksi okužbe z RSV
WO2017207477A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
MX2018014699A (es) 2016-05-30 2019-02-28 Janssen Vaccines & Prevention Bv Proteinas f de prefusion del vrs estabilizadas.
EP3595713A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. RESPIRATORY SYNCYTIAL VIRUS VACCINE
WO2018170347A1 (en) 2017-03-17 2018-09-20 Modernatx, Inc. Zoonotic disease rna vaccines
US11192926B2 (en) 2017-04-04 2021-12-07 University Of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus F proteins and their use
CA3061678A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
CA3062549A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
WO2018210871A1 (en) * 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
AU2018267971A1 (en) 2017-05-17 2019-11-07 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
EA202090738A1 (ru) * 2017-09-15 2020-06-10 Янссен Вэксинс Энд Превеншн Б.В. Способ безопасного индуцирования иммунитета против rsv
US11911453B2 (en) 2018-01-29 2024-02-27 Modernatx, Inc. RSV RNA vaccines
WO2020099383A1 (en) 2018-11-13 2020-05-22 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
EP3969044A1 (en) 2019-05-15 2022-03-23 Janssen Vaccines & Prevention B.V. Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
MX2021013947A (es) 2019-05-15 2021-12-14 Janssen Vaccines & Prevention Bv Tratamiento profilactico de la infeccion por virus sincitial respiratorio con una vacuna basada en adenovirus.
CN114502572A (zh) 2019-09-04 2022-05-13 华盛顿大学 展示副粘病毒和/或肺炎病毒f蛋白的自组装蛋白纳米结构及其用途
AU2021250630A1 (en) 2020-04-02 2022-10-20 Janssen Vaccines & Prevention B.V. Stabilized vaccine compositions
JP2022060169A (ja) 2020-10-02 2022-04-14 ファイザー・インク Ｒｓｖ ｆタンパク質生産のための細胞培養工程
CN115161344A (zh) * 2022-04-26 2022-10-11 北京智飞绿竹生物制药有限公司 一种针对呼吸道合胞病毒感染的疫苗的制备方法
WO2024067725A1 (zh) * 2022-09-29 2024-04-04 北京百邑无忧科技发展有限公司 一种融合前构象的呼吸道合胞病毒重组融合蛋白、其制备方法及用途
WO2024067723A1 (zh) * 2022-09-29 2024-04-04 北京百邑无忧科技发展有限公司 一种融合前构象的呼吸道合胞病毒重组融合蛋白、其制备方法及用途
WO2024069420A2 (en) 2022-09-29 2024-04-04 Pfizer Inc. Immunogenic compositions comprising an rsv f protein trimer
WO2024089634A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Immunogenic compositions against influenza and rsv
WO2024089633A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Rna molecules encoding rsv-f and vaccines containing them
CN117586358A (zh) * 2024-01-19 2024-02-23 北京安百胜生物科技有限公司 一种具有免疫原性的呼吸道合胞病毒（rsv）多肽

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
EP1548118A2 (en) 1994-06-10 2005-06-29 Genvec, Inc. Complementary adenoviral vector systems and cell lines
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
ATE278794T1 (de) 1995-06-15 2004-10-15 Crucell Holland Bv Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
CA2177085C (en) 1996-04-26 2007-08-14 National Research Council Of Canada Adenovirus e1-complementing cell lines
WO1998000524A1 (fr) 1996-07-01 1998-01-08 Rhone-Poulenc Rorer S.A. Procede de production d'adenovirus recombinants
FR2751343B1 (fr) 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
EP0968284B1 (en) 1996-11-20 2006-12-13 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
WO1998039411A1 (en) 1997-03-04 1998-09-11 Baxter International Inc. Adenovirus e1-complementing cell lines
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
SK11842000A3 (sk) 1998-02-17 2001-05-10 Schering Corporation Prostriedok obsahujúci vírus, spôsob jeho koncentrácie a purifikácie
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
DK1133316T3 (da) 1998-11-16 2009-05-25 Introgen Therapeutics Inc Adenovirus-formulering til genterapi
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
NZ515582A (en) 1999-05-17 2003-11-28 Crucell Holland B Adenovirus derived gene delivery vehicles comprising at least one element of adenovirus type 35
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
CA2399321C (en) 2000-03-07 2013-04-30 Robert K. Evans Adenovirus formulations
AUPR878401A0 (en) 2001-11-09 2001-12-06 Biota Holdings Ltd Methods for identifying or screening anti-viral agents
WO2003049764A1 (en) 2001-12-12 2003-06-19 Fh Faulding & Co Limited Composition for viral preservation
PL371261A1 (en) 2002-01-18 2005-06-13 Schering Aktiengesellschaft Stabilized formulations of adenovirus
US20030180936A1 (en) 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
ATE447037T1 (de) 2002-04-25 2009-11-15 Crucell Holland Bv Mittel und verfahren zur herstellung von adenovirusvektoren
ATE494362T1 (de) 2002-05-14 2011-01-15 Merck Sharp & Dohme Verfahren zur reinigung von adenovirus
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
CA2496918A1 (en) 2002-08-28 2004-03-11 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
EP1718738A2 (en) 2004-02-23 2006-11-08 Crucell Holland B.V. Virus purification methods
DK1869171T4 (en) 2005-04-11 2016-01-18 Crucell Holland Bv Virus cleaning using ultrafiltration
WO2007104792A2 (en) 2006-03-16 2007-09-20 Crucell Holland B.V. Recombinant adenoviruses based on serotype 26 and 48, and use thereof
EP1998804B1 (en) 2006-03-27 2014-04-16 Crucell Holland B.V. Compositions comprising a recombinant adenovirus and an adjuvant
US7901388B2 (en) 2007-07-13 2011-03-08 Bacoustics, Llc Method of treating wounds by creating a therapeutic solution with ultrasonic waves
DK2222710T3 (en) 2007-12-24 2016-10-03 Id Biomedical Corp Quebec Recombinant RSV antigens.
DK2350268T3 (en) 2008-11-03 2015-03-23 Crucell Holland Bv PROCEDURE FOR PRODUCING ADENOVIRUS VECTORS
WO2010149743A2 (en) 2009-06-24 2010-12-29 Id Biomedical Corporation Of Quebec Vaccine
PE20121541A1 (es) 2009-06-24 2012-12-21 Glaxosmithkline Biolog Sa Antigenos de virus de sincicio respiratorio recombinantes
EP4218799A1 (en) 2009-07-15 2023-08-02 GlaxoSmithKline Biologicals S.A. Rsv f protein compositions and methods for making same
DK2464664T3 (da) 2009-08-13 2016-01-18 Crucell Holland Bv Antistoffer mod humant respiratorisk syncytialvirus (rsv) og fremgangsmåder til anvendelse deraf
CN102791852B (zh) 2009-10-15 2014-05-07 克鲁塞尔荷兰公司 纯化腺病毒颗粒的方法
EA028875B1 (ru) 2009-10-15 2018-01-31 Янссен Вэксинс Энд Превеншн Б.В. Способ очистки аденовирусных частиц из клеточной суспензии
US20120315270A1 (en) 2009-10-21 2012-12-13 The United States Of America, As Represented By The Rsv immunogens, antibodies and compositions thereof
KR101820980B1 (ko) 2010-02-15 2018-01-22 얀센 백신스 앤드 프리벤션 비.브이. Ａｄ 26 아데노바이러스 벡터를 제조하는 방법
NZ603488A (en) 2010-07-09 2015-02-27 Crucell Holland Bv Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
LT3275892T (lt) * 2011-05-13 2020-04-10 Glaxosmithkline Biologicals S.A. Struktūros prieš suliejimą rsv f antigenai
WO2013135615A1 (en) 2012-03-12 2013-09-19 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
CA2867955C (en) 2012-03-22 2023-02-07 Crucell Holland B.V. Vaccine against rsv
JP2013247240A (ja) 2012-05-25 2013-12-09 Gigaphoton Inc レーザ装置
RU2761631C2 (ru) * 2013-03-13 2021-12-13 Дзе Юнайтед Стэйтс Оф Америка, Эс Репрезентед Бай Дзе Секретэри, Департмент Оф Хелт Энд Хьюман Сервисиз Белки rsv в предшествующей слиянию конформации и их применение
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
AU2014255865B2 (en) 2013-04-15 2019-07-18 Janssen Vaccines & Prevention B.V. Human antibodies binding to RSV G proteins
EP2986637A1 (en) 2013-04-15 2016-02-24 Crucell Holland B.V. Human antibodies binding to rsv g protein
AP2015008815A0 (en) 2013-04-25 2015-10-31 Crucell Holland Bv Stabilized soluble prefusion rsv f polypeptides
PE20160045A1 (es) 2013-06-17 2016-02-18 Crucell Holland Bv Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados

Also Published As

Publication number Publication date
JP2016522230A (ja) 2016-07-28
NZ714594A (en) 2021-07-30
EA201690031A1 (ru) 2016-07-29
CN105408348B (zh) 2021-07-06
WO2014202570A1 (en) 2014-12-24
JP6679475B2 (ja) 2020-04-15
MX362792B (es) 2019-02-13
KR102313153B1 (ko) 2021-10-15
AU2014283334A1 (en) 2015-12-17
HK1223949A1 (zh) 2017-08-11
AP2015008893A0 (en) 2015-12-31
EP3010931B1 (en) 2018-06-13
CL2015003655A1 (es) 2016-06-03
MX2015017771A (es) 2016-10-04
US20160176932A1 (en) 2016-06-23
MY171210A (en) 2019-10-02
BR112015031509B1 (pt) 2023-05-09
EA034653B1 (ru) 2020-03-03
US10294279B2 (en) 2019-05-21
AU2014283334B2 (en) 2018-10-18
PH12015502735B1 (en) 2016-03-07
CN105408348A (zh) 2016-03-16
IL243053B (en) 2020-06-30
KR20160021196A (ko) 2016-02-24
ZA201509140B (en) 2022-03-30
CA2914792A1 (en) 2014-12-24
PE20160045A1 (es) 2016-02-18
EP3010931A1 (en) 2016-04-27
SG11201510216RA (en) 2016-01-28
PH12015502735A1 (en) 2016-03-07
CA2914792C (en) 2024-02-27

Similar Documents

Publication Publication Date Title
BR112015031509A2 (pt) Polipeptídeo, molécula de ácido nucleico, vetor, e, composição
BR112017028449A2 (pt) polipeptídeos rsv f pré-fusão solúveis estabilizados
CY1121600T1 (el) Σταθεροποιημενα διαλυτα πολυπεπτιδια rsv f προσυντηξης
BR112018070013A2 (pt) proteínas f do rsv pré-fusão solúveis estabilizadas
MX2021007679A (es) Anticuerpos humanos para hemaglutinina de influenza.
BR112017013491A2 (pt) compostos de pirimidina fundida para o tratamento de hiv
BR112017025892A2 (pt) vetores de vírus adeno-associados para o tratamento de mucolopissacaridoses
BR112018074483A2 (pt) proteínas f do rsv pré-fusão estabilizadas
BR112017013440A2 (pt) compostos de isoquinolina para o tratamento de hiv
BR112014022214A2 (pt) fenólicos antibacterianos
ECSP21042554A (es) Proteínas f de prefusión del vrs estabilizadas
BR112017024039B8 (pt) Piroglutamato de vortioxetina, composições farmacêuticas e gel compreendendo o mesmo, método para preparar um gel, e usos do piroglutamato de vortioxetina para fabricação de um medicamento ou gel
PH12017502356A1 (en) Immunoglobulin single variable domain antibody against rsv prefusion f protein
AR095869A1 (es) Anticuerpos humanos que se unen a la proteína g del rsv
IN2013MU01983A (pt)

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: JANSSEN VACCINES AND PREVENTION B.V (NL)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25G Requested change of headquarter approved

Owner name: JANSSEN VACCINES AND PREVENTION B.V. (NL)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/06/2014, OBSERVADAS AS CONDICOES LEGAIS